Syndax Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $37,958 | $20,042 | $7,680 | $12,500 |
Gross Profit | 36,679 | 19,157 | 6,854 | 12,498 |
EBITDA | -63,989 | -83,757 | -89,363 | -84,101 |
EBIT | -92,895 | -96,365 | -84,103 | |
Net Income | -71,847 | -84,846 | -94,169 | -84,126 |
Net Change In Cash | 37,958 | 20,042 | 7,680 | 12,500 |
Free Cash Flow | -87,795 | -95,162 | -57,388 | -62,322 |
Cash | 108,636 | 153,993 | 154,083 | 133,019 |
Basic Shares | 86,337 | 85,622 | 85,791 | 85,434 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $23,680 | $0 | $126,576 | $139,709 |
Gross Profit | 22,854 | -12 | -454 | 139,709 |
EBITDA | -313,821 | -229,942 | -151,724 | 26,263 |
EBIT | -313,829 | -229,954 | -151,757 | 26,220 |
Net Income | -318,758 | -209,360 | -143,749 | 24,926 |
Net Change In Cash | 23,680 | 0 | 126,576 | 139,709 |
Cost of Revenue | 106,722 | |||
Free Cash Flow | -274,903 | -160,601 | -133,900 | 29,002 |
Cash | 154,083 | 295,394 | 74,356 | 221,965 |
Basic Shares | 85,622 | 70,370 | 60,760 | 53,622 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.83 |
2025-03-31 | -$0.98 |
2024-12-31 | -$1.10 |
